Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 914 participants.
Also called NCT04950920
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 914 participants
- Registry
-
NCT04950920
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04950920. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-28 (actual); primary completion 2022-08-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke
- Condition
- Stroke
- Intervention (Drug)
- Y-2 sublingual tablets
- Intervention (Drug)
- d-borneol
- Lead sponsor
- Peking University Third Hospital
Record details
- Record id
cardio:ct-nct04950920- Content hash
0adfeb93bb3dd1bf001fda911468ff3d61124509ce82ff94f99e5eacc965deb6